BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced that final results from the Phase 3 METIS trial of Tumor Treating Fields (TTFields) therapy for brain metastases from non-small ...
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback